ProJect Pharma and TUM-spin-off link on H. pylori vaccine development

Germany-based ProJect Pharmaceutics has signed a development agreement with ImevaX, a spin-off project from the research group Markus Gerhard from the Technische Universitat Munchen, Institute for Medicinal Microbiology, Immunology and Hygiene.

The collaboration is aimed at developing a formulation for a recombinant vaccine against Helicobacter pylori. IMX101 is a multi-component vaccine, making the formulation development particularly challenging, the company noted. Financial terms of the current agreement are not disclosed.

The contract covers activities in developing a rational formulation based on ProJect Pharmaceutics´ Predictive Formulation Analytics. This technology offers an innovative scientific approach for designing optimized protein formulations by determining the most favorable composition for the native structure of the protein with regard to its intra- and intermolecular physicochemical properties. By analyzing the response to certain excipients the most promising formulation candidates can be identified quickly and reliably reducing the need for extensive stability testing.